Who Paid My Doc
A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An
Research payments
$12,604,985
Through program year 2024, $12,604,985 in research payments was reported against A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An, across 3,957 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $4,598 | 4 |
| 2023 | Research | $932,639 | 202 |
| 2022 | Research | $951,919 | 1,257 |
| 2021 | Research | $4,046,260 | 1,068 |
| 2020 | Research | $5,799,316 | 1,260 |
| 2019 | Research | $870,253 | 166 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Tamar Brionez The Woodlands, TX Named on 145 payments
- Dhiman Basu Colleyville, TX Named on 88 payments
- Liliam Hernandez Miami, FL Named on 79 payments
- Benidecto Fernandez Hialeah, FL Named on 70 payments
- Swati Bharadwaj Phoenix, AZ Named on 69 payments
- Ralph Bennett Phoenix, AZ Named on 65 payments
- Melvin Churchill Lincoln, NE Named on 58 payments
- Yong Tsai Palm Coast, FL Named on 57 payments
- Farrukh Zaidi Port Richey, FL Named on 55 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.